United Therapeutics (UTHR) Research & Development (2009 - 2026)

United Therapeutics has reported Research & Development for 18 years, with the latest figure at $138.2 million in Q1 2026.

• Quarterly Research & Development fell 7.25% year-over-year to $138.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $539.2 million (up 2.53% YoY) and the FY2025 annual result came in at $550.0 million, up 14.35% from the prior year.
• Research & Development slipped to $138.2 million in Q1 2026 per UTHR's latest filing, from $139.5 million in the prior quarter.
• Over five years, Research & Development peaked at $151.4 million in Q4 2023 and troughed at $66.1 million in Q3 2022.
• A 5-year average of $111.8 million and a median of $104.1 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development sank 77.28% in 2022, then surged 61.24% in 2023.
• Over 5 years, Research & Development stood at $93.9 million in 2022, then soared by 61.24% to $151.4 million in 2023, then retreated by 11.62% to $133.8 million in 2024, then grew by 4.26% to $139.5 million in 2025, then retreated by 0.93% to $138.2 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $138.2 million, $139.5 million, and $127.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.